Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.
I think it’s cool that there are other therapies that are hopefully going to be approved in the near future that are more—not to say traditional, but they’ll [provide] more options for our patients who are ineligible for CAR T or bispecific antibody therapy.
Secondly, most of the approved agents, from a cellular immunotherapy perspective, are based on harnessing the power of T cells, but there are other agents on their heels trying to harness the anti-tumor effects of other immune populations, like macrophages or natural killer cells. That's going to be a cool next step. [It’s going to be interesting to see] how we can use other arms of a patient’s immune system to affect the anti-myeloma activity of therapy.
Transcript edited for clarity.